Editing Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)

'''See Original Guideline'''

== Definitions ==

* '''Adjuvant radiotherapy (ART): administration of RT to post-radical prostatectomy (RP) patients at a higher risk of recurrence because of adverse pathological features prior to evidence of disease recurrence (i.e., with an undetectable PSA)'''
* '''Salvage radiotherapy (SRT): administration of RT''' to the prostatic bed and possibly to the surrounding tissues, including lymph nodes, '''in the patient with PSA recurrence after surgery but no evidence of distant metastatic disease'''
** '''Biochemical recurrence after surgery is defined as a detectable PSA level > 0.2 ng/mL with a second confirmatory level > 0.2 ng/mL.'''

* '''Patients with adverse pathology detected at prostatectomy who have a persistent post-prostatectomy PSA level should be offered post-RP SRT''' (not technically adjuvant since no period without disease) [source?]

== '''ART vs. SRT''' ==

* '''Advantages/disadvantages'''
** '''Overtreatment with ART:''' ART may involve irradiation of some patients who never would have had recurrent cancer, thus exposing them unnecessarily to the risks, toxicity, and QoL impact of RT. SRT avoids overtreatment.
** '''Delayed treatment with SRT:''' waiting to administer RT as a salvage therapy could be less effective, particularly in patients with high-risk disease, and could allow the progression to metastatic disease.
*** Observational studies suggest that ART patients generally have better outcomes compared to SRT patients. However, this is difficult to compare these groups that SRT studies focus only on patients who have already relapsed and the ART group has patients that were never destined to recur
*** '''No published trials comparing ART to SRT'''
**** '''Pending publication: RADICALS'''
* '''[At the time of guideline publication,] insufficient evidence to determine superiority of ART vs. SRT'''

===== '''ART''' =====

* '''Patients who undergo RP for localized prostate cancer should be informed of the potential for adverse pathologic findings that increase risk of cancer recurrence and that these findings may suggest a potential benefit of additional therapy after surgery.'''
** '''The first PSA generally should be obtained 2-3 months post-RP'''
** Recurrence after RP is thought to result from residual subclinical disease in the operative site or occult metastatic disease that was present at the time of the prostatectomy
** '''The risk of recurrence is greater among men with adverse pathology, such as positive surgical margins, seminal vesicle invasion, extraprostatic extension, and higher Gleason scores'''
** Rates of recurrence in post-RP patients with adverse pathological features may be > 60% at 5 years post-RP
* '''ART should be offered to patients with adverse pathologic findings (seminal vesicle invasion, positive surgical margins, or extraprostatic extension) at prostatectomy'''
** '''3 RCTs (SWOG 8794, EORTC 22911, and ARO 96-02) randomized patients with adverse pathological features at prostatectomy to ART vs. observation'''
*** '''See Management of Locally Advanced Prostate Cancer Notes'''
*** All 3 trials have > 10 years follow-up
*** All 3 trials documented significant improvements in biochemical RFS with use of ART.
**** The Panel notes that prevention of biochemical progression is an important clinical endpoint because biochemical progression may trigger salvage therapy (i.e., hormone therapy), with its associated toxicities (increased risks for osteoporosis, cardiovascular disease and other health problems with ADT) and QoL impact. In addition, patients with biochemical recurrence are more likely to manifest metastatic recurrence. Therapies for metastatic recurrence, such as hormone therapies, can also have profound QoL impact.
*** The 2 RCTs that evaluated locoregional failure (SWOG 8794; EORTC 22911) demonstrated a reduction in locoregional failure with ART
*** Both SWOG 8794 and EORTC 22911 reported statistically significant reductions in the use of subsequent salvage therapies with ART
*** SWOG 8794 and EORTC 22911 demonstrated improved cPFS (defined as clinical or imaging evidence of recurrence or death but not including biochemical progression) with ART
*** '''2 of the trials, SWOG 8794 and EORTC 22911, assessed metastatic recurrence and OS'''. '''Only SWOG 8794 demonstrated significantly improved metastatic recurrence-free survival and overall survival;''' ARO-96-02 and EORTC were not designed to identify a significant reduction in metastasis or death with adjuvant radiotherapy